ArticleMetabolic brain disease2025
Alterations in serum nudifloramide associated with response to diverse pharmacological treatments in major depressive disorder: a preliminary study.
Article in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Pharmacological treatments for major depressive disorder (MDD) have limited efficacy, underscoring the need for biomarkers to assess treatment response. Metabolomics enables characterization of metabolic alterations associated with antidepressant effectiveness. This cross-sectional study aimed to discover and validate metabolite biomarkers that can be used to screen responses to drug treatment in MDD through a metabolomics-based approach. Serum samples from drug-treated MDD patients with persistent depression (D-MDD), patients in remission (R-MDD), and healthy controls were divided into discovery (D-MDD: n=19, R-MDD: n=17, control: n=25) and validation (D-MDD: n=36, R-MDD: n=30, control: n=65) sets. Untargeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis identified candidate metabolites, which were validated using multiple reaction monitoring. L-histidine and nudifloramide were identified in the discovery phase. L-histidine increased stepwise from D-MDD to R-MDD to controls, but significance was lost in validation. Nudifloramide showed a similar trend; in validation, its concentration was significantly higher in controls than in D-MDD, with R-MDD at intermediate levels approaching controls. Alterations in nudifloramide suggest involvement of the tryptophan-kynurenine pathway and NAD⁺ homeostasis in MDD pathophysiology and treatment response. Nudifloramide may serve as a biomarker for distinguishing depressed from healthy states in treated patients. Further pathway-focused studies are warranted.
Indexed as
Identifiers
41065915What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.